{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-021560","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.195146+00:00","generated_at":"2026-05-17T22:59:40.549691+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Propanc Biopharma enters $112,350 convertible note at 22% interest with 1800 Diagonal Lending","bullets":["Issued $112,350 convertible promissory note to 1800 Diagonal Lending LLC at a 22% annual interest rate.","Conversion price is 75% of average lowest trading price over 10 days prior to conversion, with 4.99% beneficial ownership cap.","Maturity date April 30, 2026; company can prepay at 120% premium within 90 days, 125% from 91-180 days.","Proceeds from $107,000 purchase price (after $5,350 original issue discount) used for general working capital.","Events of default include failure to pay, failure to issue conversion shares, and loss of OTC listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-021560","json":"https://secwatch.observer/filing/0001641172-25-021560.json","markdown":"https://secwatch.observer/filing/0001641172-25-021560.md","text":"https://secwatch.observer/filing/0001641172-25-021560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000164117225021560/0001641172-25-021560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000164117225021560/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T22:59:40.549691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a6dd24d51f24f7f4d373e11a6feb90be3ade104","claim":"Propanc Biopharma, Inc. incurred convertible notes of $112,350 at 22% per annum maturing April 30, 2026.","evidence_excerpt":"Effective July 25, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $112,350 (the “Note”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000164117225021560/0001641172-25-021560-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$112,350"},{"label":"Rate","value":"22% per annum"},{"label":"Maturity","value":"April 30, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}